In contrast, the recurrent vitreous hemorrhage (VH) rate (≤6.7%) was significantly lower than literature-reported values (10–20%), a disparity potentially attributable to systematic preoperative anti-VEGF administration. Here, VEGFA is linked to vitreous hemorrhage.